Company: CERO
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044335
Chunk: 8

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 1
Chunk 8
---
 receivable  
     716,694  
     -  
     - 
  
    Proceeds received from sale of common stock 
     588,000  
     -  
     - 
  
    Proceeds received from sale of pre-funded warrants, net of issuance costs 
     3,685,027  
     -  
     - 
  
    Proceeds from exercise of pre-funded warrants 
     182  

    Cash redemption of Series C Preferred Stock 
     (395,000) 
     -  
     - 
  
    Net cash provided by financing activities 
     6,322,144  
     7,157,766  
     - 

    Net increase (decrease) in cash and cash equivalents 
     1,876,477  
     2,715,108  
     (637,400)

    Cash, restricted cash and cash equivalents at beginning of period 
     3,327,060  
     1,877,995  
     1,601,255 

    Cash, restricted cash and cash equivalents at end of period 
    $5,203,537  
    $4,593,103  
    $963,855 

    SUPPLEMENTAL CASH FLOW INFORMATION: 

    Cash and cash equivalents 
    $5,128,781  
    $4,513,347  
    $963,855 
  
    Restricted cash 
     74,756  
     79,756  
     - 
  
    Cash, restricted cash and cash equivalents 
    $5,203,537  
    $4,593,103  
    $963,855 

    NON-CASH FINANCING ACTIVITIES: 

    Issuance of common shares to Keystone Capital LLC for equity line of credit 
    $-  
     633,345  
    $- 
  
    Issuance of Series B shares under subscription agreements 
    $-  
    $500,000  
    $- 
  
    Conversion of Series A and Series B preferred stock to common stock 
    $980,985  
    $-  
    $- 
  
    Reclassification of deferred offering costs to additional paid-in capital 
    $112,232  
    $-  
    $- 
  
    Rec